1. Generics Bulletin
  2. >>Business

No Single Biosimilars Model Fits Europe, Says Samsung Bioepis’ Ko

Brazil Is Also A Key Part Of The Firm’s Strategy

 
• By Dave Wallace

In the second part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko sets out the firm’s strategy in Europe, as well as the importance of Brazil and China to its future plans.

One size
Individual European markets require different models, Ko believes • Source: Shutterstock

As CEO of the Samsung Bioepis joint venture between Samsung BioLogics and Biogen, Christopher Hansung Ko oversees a major player in the global biosimilars market.

While the firm has significant interests in the US – as explored in the first part of our exclusive interview with Ko (Also see "Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko" - Generics Bulletin, 21 October, 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.